Home › Funds › Caligan Partners LP › EXEL

Caligan Partners LP position in EXEL

EXELIXIS INC · Health Care

Caligan Partners LP reported holding 1,553,262 shares of EXEL (EXELIXIS INC) in its Q2 2026 13F filing — a position valued at US$84.5M, representing 4.94% of its reported portfolio and ranking #4 among its reported holdings. Caligan Partners LP has disclosed EXEL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.55M sh
Reported value held$84.51M
Portfolio Weight4.94%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Caligan Partners LP's EXEL position evolved

Caligan Partners LP first disclosed a stake in EXEL in Q3 2023 at 910,730 shares (US$19.9M). The position peaked in Q2 2026 at 1,553,262 shares, worth US$84.5M. Across 12 filings, Caligan Partners LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 1,553,262 shares valued at US$84.5M. Notable position changes include a 39% increase in Q2 2024 (shares rose 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 910.73K $19.90M New
Q4 2023 910.73K $21.85M Hold
Q1 2024 1.10M $26.12M Add
Q2 2024 1.53M $34.28M Add
Q3 2024 1.53M $39.59M Hold
Q4 2024 1.53M $50.81M Hold
Q1 2025 1.53M $56.33M Hold
Q2 2025 1.53M $67.25M Hold
Q3 2025 1.53M $63.01M Hold
Q4 2025 1.55M $68.08M Add
Q1 2026 1.55M $66.62M Hold
Q2 2026 1.55M $84.51M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EXEL and 13F data

EXEL (EXELIXIS INC) is a Health Care company. 41 other funds we track also report a position in EXEL — the largest reported positions include Farallon Capital Management (US$732.8M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$732.8M), Renaissance Technologies (US$730.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EXEL

All EXEL fund holders →

FAQ

How long has Caligan Partners LP held EXEL?

Caligan Partners LP has disclosed EXEL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Caligan Partners LP's current position in EXEL?

As of Q2 2026, Caligan Partners LP holds 1.55M shares of EXEL (EXELIXIS INC), valued at $84.51M, representing 4.94% of its reported portfolio and ranking #4.

Has Caligan Partners LP been buying or selling EXEL?

In the latest 13F filing (Q2 2026), Caligan Partners LP held unchanged its position in EXEL. The position peaked in Q2 2026 at 1.55M shares.

Which other funds hold EXEL?

Other major institutional holders of EXEL include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., Renaissance Technologies, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.